Literature DB >> 26734644

MicroRNAs in multiple myeloma and related bone disease.

Marco Rossi1, Pierosandro Tagliaferri1, Pierfrancesco Tassone1.   

Abstract

MicroRNAs (miRNAs) are short non coding RNAs aberrantly expressed in solid and hematopoietic malignancies where they play a pivotal function as post-transcriptional regulators of gene expression. Recent reports have unveiled a central role of miRNAs in multiple myeloma onset and progression and preclinical findings are progressively disclosing their potential therapeutic value as drugs or targets. In this review, we provide the basic insights of miRNA biology and function, showing how these molecules are extensively dysregulated in malignant plasma cells (PC) and related microenvironment, thus favoring clone survival and proliferation. We here describe how these critical activities have recently been evaluated to design miRNA-based therapies against multiple myeloma cells and its surrounding microenvironment.

Entities:  

Keywords:  MicroRNAs (miRNAs); miRNA therapy; multiple myeloma (MM) bone disease; non coding RNAs

Year:  2015        PMID: 26734644      PMCID: PMC4690997          DOI: 10.3978/j.issn.2305-5839.2015.12.13

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  91 in total

Review 1.  Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?

Authors:  Pierfrancesco Tassone; Pierosandro Tagliaferri; Marco Rossi; Marco Gaspari; Rosa Terracciano; Salvatore Venuta
Journal:  Eur J Cancer       Date:  2006-07-03       Impact factor: 9.162

2.  Discovery of functional miRNA-mRNA regulatory modules with computational methods.

Authors:  Bing Liu; Jiuyong Li; Anna Tsykin
Journal:  J Biomed Inform       Date:  2009-01-30       Impact factor: 6.317

3.  Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells.

Authors:  Maoxiao Feng; Xiaochuang Luo; Chunming Gu; Jia Fei
Journal:  J Drug Target       Date:  2014-09-04       Impact factor: 5.121

4.  A SCID-hu in vivo model of human Waldenström macroglobulinemia.

Authors:  Pierfrancesco Tassone; Paola Neri; Jeffery L Kutok; Olivier Tournilhac; Daniel Ditzel Santos; Evdoxia Hatjiharissi; Vidit Munshi; Salvatore Venuta; Kenneth C Anderson; Steven P Treon; Nikhil C Munshi
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

5.  MiR-155 at the heart of oncogenic pathways.

Authors:  M F Czyzyk-Krzeska; X Zhang
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

Review 6.  Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.

Authors:  P Tassone; P Tagliaferri; M Rossi; T Calimeri; A Bulotta; A Abbruzzese; M Caraglia; P Neri
Journal:  Curr Cancer Drug Targets       Date:  2009-11       Impact factor: 3.428

7.  Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.

Authors:  R S Geary; R Z Yu; A A Levin
Journal:  Curr Opin Investig Drugs       Date:  2001-04

8.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Authors:  Andrea L Kasinski; Frank J Slack
Journal:  Cancer Res       Date:  2012-09-10       Impact factor: 12.701

Review 9.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

10.  The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Authors:  Di Zhu; Zhongqiu Wang; Jian-Jun Zhao; Teresa Calimeri; Jiang Meng; Teru Hideshima; Mariateresa Fulciniti; Yue Kang; Scott B Ficarro; Yu-Tzu Tai; Zachary Hunter; Douglas McMilin; Haoxuan Tong; Constantine S Mitsiades; Catherine J Wu; Steven P Treon; David M Dorfman; Geraldine Pinkus; Nikhil C Munshi; Pierfrancesco Tassone; Jarrod A Marto; Kenneth C Anderson; Ruben D Carrasco
Journal:  Nat Med       Date:  2015-05-25       Impact factor: 53.440

View more
  8 in total

1.  MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.

Authors:  Tianhua Yu; Xuanhe Zhang; Lirong Zhang; Yali Wang; Hongjuan Pan; Zhihua Xu; Xiaochuan Pang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 2.  MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Authors:  Luna Soley; Carolyne Falank; Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 3.  Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.

Authors:  Jing-di Liu; Chun-Yan Sun; Liang Tang; Ying-Ying Wu; Qing-Yun Wang; Bei Hu; Yu Hu
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

4.  Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Authors:  Maria Pia Abruzzese; Maria Teresa Bilotta; Cinzia Fionda; Alessandra Zingoni; Alessandra Soriani; Elisabetta Vulpis; Cristiana Borrelli; Beatrice Zitti; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rosa Molfetta; Rossella Paolini; Angela Santoni; Marco Cippitelli
Journal:  J Hematol Oncol       Date:  2016-12-01       Impact factor: 17.388

Review 5.  DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Authors:  Mariamena Arbitrio; Maria Teresa Di Martino; Francesca Scionti; Giuseppe Agapito; Pietro Hiram Guzzi; Mario Cannataro; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Oncotarget       Date:  2016-08-16

Review 6.  The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma.

Authors:  Bingying Zhu; Shaoqing Ju; Haidan Chu; Xianjuan Shen; Yan Zhang; Xi Luo; Hui Cong
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 7.  The biological significance of histone modifiers in multiple myeloma: clinical applications.

Authors:  Hiroto Ohguchi; Teru Hideshima; Kenneth C Anderson
Journal:  Blood Cancer J       Date:  2018-08-22       Impact factor: 11.037

8.  Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways.

Authors:  Chaimaa Saadoune; Badreddine Nouadi; Hasna Hamdaoui; Fatima Chegdani; Faiza Bennis
Journal:  Bioinform Biol Insights       Date:  2022-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.